Navigation Links
NOVAVAX Reports Third Quarter 2010 Financial Results
Date:11/5/2010

statements contained in this release.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates into pre-clinical or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even with positive data from pre-clinical studies or clinical trials, the product candidate may not prove to be safe and efficacious; decisions by regulatory agencies may delay or prevent our development programs or increase the costs of such programs; regulatory approval is needed before any we can initiate clinical trials on our vaccines; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next influenza season, if at all; RSV is a difficult disease to prevent and there is significant activity by many companies toward the development of a suitable vaccine; we have not manufactured any of our vaccine candidates at a commercial level; we utilize a unique manufacturing process and the scale-up of that process may prove difficult and/or costly; our dependence on third parties to manufacture and distribute our vaccines; risks associated with conducting business outside of the United States; the cost and our ability of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competition for clinical resources and patient enrollment from drug candidates in developm
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
2. NOVAVAX to Present at BIO Investor Forum
3. NOVAVAX to Present at Stifel Nicolaus Conference
4. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
5. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
7. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
8. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
9. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
10. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
... SPRING, Md., Nov. 8, 2011 The U.S. Food and Drug ... and caregivers on the safe disposal of needles and other ... while traveling. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... created by improperly disposing of used sharps and how users ...
Cached Medicine Technology:James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 2FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 3FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 4
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers . , “Fun, cool, and ... Citrus theme” Says Christina Austin, CEO of Pixel Film Studios. ... , Citrus comes with all the tools needed for a ... transitions for added style, a title screen for an introduction, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... ... ... ... ...
... has identified four aspects of immune system disturbance which ... different inherited risk factors which predispose to the disease ... the way towards improved diagnostics and treatments for the ... population, and lead to insights into related conditions such ...
... PCI Data Compliance ... ... card processing company for small to medium sized businesses. Recently, North American Bancard has ... provide the small to medium sized businesses of the area to take advantage of face-to-face ...
... Allergens not linked to wheezing in kids, study finds , ... early in life doesn,t affect a child,s risk of developing ... that infants were exposed to high levels of endotoxin and ... were anxious to find out, through a birth cohort study, ...
... exposure during pregnancy might increase chances of condition , ... mothers were exposed to a common but controversial chemical ... A (BPA) is a chemical commonly found in polycarbonate ... beverage cans. Production of the chemical started about 40 ...
... ... ... ... ...
Cached Medicine News:Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 2Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 3Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 4Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 5Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 6Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 7Health News:Multiple Medalist Kristina Groves Matches Hain Celestial's $5,000 Donation to Right to Play 8Health News:Pinpointing immune system disturbances in celiac disease 2Health News:North American Bancard in the Tri-Cities Area of East Tennessee 2Health News:Household Dirt Won't Raise Asthma Risk in Infants 2Health News:BPA May Raise Risk of Asthma in Kids 2Health News:BPA May Raise Risk of Asthma in Kids 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 2Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 3Health News:CareTech Solutions Presents Specialized Healthcare Call Center at HIMSS10 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: